Takehide Iwasa

Director/Board Member at Karydo TherapeutiX, Inc.

48 year

Health Technology

Commercial Services

Profile

Takehide Iwasa is currently a Director at Karydo TherapeutiX, Inc., Allgene, Inc., and Biomedica Solution KK.
He was previously a Director & General Manager-Sales at tella, Inc.

Takehide Iwasa active positions

Companies	Position	Start
Karydo TherapeutiX, Inc. Karydo TherapeutiX, Inc. Miscellaneous Commercial ServicesCommercial Services Karydo TherapeutiX, Inc. develops technologies to detect the earliest signs of diseases. Its proprietary technology includes “iOrgans Technology.” This technology consists of three sub-technologies: Reverse-iOrgans (R-iOrgans,) Forward-iOrgans (F-iOrgans) and Drug-iOrgans (D-iOrgans.) They all use iOrgans Indicators (iOrgans-Id) to effectively and efficiently detect the earliest signs of diseases (R-iOrgans,) and to pre-empt them (F-iOrgans.) This technology can be also used to discover effects of drugs (D-iOrgans.) The company was founded by Thomas Sato on October 15, 2015 and is headquartered in Tokyo, Japan.	Director/Board Member	30/09/2015
Allgene, Inc.	Director/Board Member	30/11/2015
Biomedica Solution KK Biomedica Solution KK BiotechnologyHealth Technology Part of Tella, Inc., Biomedica Solution KK is a Japanese company that manufactures cell production facilities.	Director/Board Member	-

All active positions of Takehide Iwasa

Former positions of Takehide Iwasa

Companies	Position	End
TELLA, INC.	Director/Board Member	-

See the detail of Takehide Iwasa's experience

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Takehide Iwasa's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	4
tella, Inc. tella, Inc. BiotechnologyHealth Technology tella, Inc. engages in research and development of dendritic cell (DC) vaccine therapy. It operates through the following segments: Cell Medicine, Medical Support, and Pharmaceuticals. The Cell Medicine segment provides cancer treatment technology and know-hows centered on dendritic cell vaccine therapy. The Medical Support segment manages contact research organization (CRO) business and offers genetic testing services. The Pharmaceuticals segment deals with the development of dendritic cell vaccine as a cancer treatment. The company was founded by Yuichiro Yazaki on June 24, 2004 and is headquartered in Tokyo, Japan.	Health Technology
Karydo TherapeutiX, Inc. Karydo TherapeutiX, Inc. Miscellaneous Commercial ServicesCommercial Services Karydo TherapeutiX, Inc. develops technologies to detect the earliest signs of diseases. Its proprietary technology includes “iOrgans Technology.” This technology consists of three sub-technologies: Reverse-iOrgans (R-iOrgans,) Forward-iOrgans (F-iOrgans) and Drug-iOrgans (D-iOrgans.) They all use iOrgans Indicators (iOrgans-Id) to effectively and efficiently detect the earliest signs of diseases (R-iOrgans,) and to pre-empt them (F-iOrgans.) This technology can be also used to discover effects of drugs (D-iOrgans.) The company was founded by Thomas Sato on October 15, 2015 and is headquartered in Tokyo, Japan.	Commercial Services
Allgene, Inc.
Biomedica Solution KK Biomedica Solution KK BiotechnologyHealth Technology Part of Tella, Inc., Biomedica Solution KK is a Japanese company that manufactures cell production facilities.	Health Technology

See company connections

Stock Market
Insiders
Takehide Iwasa